ArticleBreast cancer research : BCR2026
Exploring LTB-mediated T cell differentiation as a prognostic marker in triple-negative breast cancer.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Immune infiltration in triple-negative breast cancer (TNBC) is associated with patient prognosis. However, the precise phenotypic classifications of immune infiltration in TNBC remain unclear, and the key regulatory mechanisms underlying this process require further investigation. In this study, we employed transcriptomic and single-cell data analysis, utilizing unsupervised clustering to classify the immune microenvironment of TNBC. We constructed a prognostic model based on immune phenotypes and further validated the regulatory role of key genes in immune cell modulation. Through unsupervised clustering analysis of the GEO and METABRIC databases, we identified two distinct immune infiltration phenotypes in TNBC tumor tissues. Notably, patients with high immune infiltration exhibited significantly prolonged overall survival (OS). Subsequent analysis of tumor tissues from high/low immune infiltration groups revealed five differentially expressed genes (DEGs), which were significantly correlated with patient prognosis: lymphotoxin β (LTB), interferon regulatory factor 8 (IRF8), indoleamine 2,3-dioxygenase 1 (IDO1), integral membrane protein 2A (ITM2A), and lymphocyte cytosolic protein 1 (LCP1). A prognostic model for TNBC was developed based on the five key genes. Furthermore, we demonstrated a significant association between LTB expression and enhanced immune effects in TNBC tissues. Single-cell sequencing data revealed that LTB expression was predominantly localized to immune-infiltrating T cells, which tended to differentiate toward cytotoxic T cells. We also confirmed that LTB expression improved T cell proliferation and enhanced the tumoricidal effect by modulating T cell differentiation pathways. In conclusion, immune infiltration phenotype is a crucial prognostic biomarker for TNBC patients. LTB contributes to enhanced immune infiltration, making as a promising target for immune therapy in TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.